SLN (Silence Therapeutics) Total Liabilities : $68.61 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Total Liabilities?

Silence Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 was $68.61 Mil.

Silence Therapeutics's quarterly Total Liabilities increased from Jun. 2024 ($96.29 Mil) to Sep. 2024 ($100.19 Mil) but then declined from Sep. 2024 ($100.19 Mil) to Dec. 2024 ($68.61 Mil).

Silence Therapeutics's annual Total Liabilities declined from Dec. 2022 ($103.39 Mil) to Dec. 2023 ($97.46 Mil) and declined from Dec. 2023 ($97.46 Mil) to Dec. 2024 ($68.61 Mil).

Silence Therapeutics Total Liabilities Historical Data

The historical data trend for Silence Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Total Liabilities Chart

Silence Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

104.82

118.32

103.39

97.46

68.61

Silence Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															97.46	88.98	96.29	100.19	68.61

Silence Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Silence Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16.822	+	(0	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	51.79	+	0	+	0)
	=	68.61

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	202.635	-	134.023
	=	68.61

Silence Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16.822	+	(0	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	51.79	+	0	+	0)
	=	68.61

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	202.635	-	134.023
	=	68.61

Silence Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.